Legend Biotech Corporation - American Depositary Shares (LEGN)
26.71
+1.13 (4.44%)
NASDAQ · Last Trade: May 12th, 1:52 PM EDT
Detailed Quote
Previous Close
25.58
Open
24.63
Bid
26.66
Ask
26.77
Day's Range
24.30 - 27.11
52 Week Range
16.24 - 45.30
Volume
2,840,926
Market Cap
8.24B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,855,047
Chart
About Legend Biotech Corporation - American Depositary Shares (LEGN)
Legend Biotech Corp is a biotechnology company focused on the development and commercialization of innovative cell therapies for the treatment of cancer and other serious diseases. The company leverages its proprietary technologies to create advanced cellular therapies, particularly in the realm of engineered T cell therapy, aiming to harness the body's immune system to target and eliminate malignant cells. Through rigorous research and clinical trials, Legend Biotech is committed to addressing unmet medical needs and enhancing patient outcomes in the field of oncology. Read More
Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded.
Chief Executive Officer Ying Huang said the company beg
SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highlights.
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.
SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2025, and key corporate highlights.
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results.
Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will lead to sustainable growth.
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence
SOMERSET, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today provided an update on the Company's recent commercial and clinical progress and outlined its strategic priorities for 2026. These updates will be discussed as part of the Company's presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 9:00 a.m. PT.
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14th, 2026, at 9:00 a.m. PT.
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival (mPFS) of 50.4 months was observed following a single infusion of CARVYKTI®. This represents one of the longest PFS outcomes reported for a BCMA-targeted CAR-T cell therapy in this heavily pretreated population.
